November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to ...

Worldwide names John Capicchioni as SVP, Commercial, Early Phase to lead business development and commercial activities for ...

Imneskibart will now enter late-stage trials after the drug offered durable tumour shrinkage in NSCLC, melanoma and other ...

Ontada®, a leader in real-world oncology data and insights, presents new research findings in an oral presentation at ISPOR Europe 2025.

Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Intellia Therapeutics (NTLA) announced “positive” follow-up data from the ongoing Phase 1 clinical trial of its investigational product nexiguran ...

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...

Akebia Therapeutics shares retreated Monday after the company dropped plans for a Phase 3 clinical trial of its drug Vafseo for certain patients. Shares were trading at $1.66, down 19% and nearing the ...

AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis (UC) after the PD-1 agonist flunked a phase 2 study.

Psyence Biomedical (PBM) announced a major clinical milestone with multiple patients successfully dosed in its ongoing Phase IIb clinical trial ...

Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical ...

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the ...